Korean company’s Alzheimer’s disease treatment concludes phase II trials
22010
post-template-default,single,single-post,postid-22010,single-format-standard,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-title-hidden,transparent_content,qode-theme-ver-18.2,qode-theme-bridge,disabled_footer_bottom,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.5,vc_responsive

Korean company’s Alzheimer’s disease treatment concludes phase II trials

Korean biotechnology company AriBio Co Ltd’s new drug to treat Alzheimer’s disease has completed phase II trials. The results show that the drug, AR1001, acts against the protein which forms amyloid plaques that can disrupt healthy cell functioning in Alzheimer’s.

Early analysis also suggests that the drug inhibits neuron cell death and restores the ability to strengthen connections between neurons.

The trials consisted of 210 participants and results are expected to be published in early 2021.

Click here to read more.